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a  b  s  t  r  a  c  t
Objectives: Identify good response predictors to intra-articular injection (IAI) with triamci-
nolone hexacetonide (TH).
Methods: This study was carried out in rheumatoid arthritis (RA) patients (American College
of  Rheumatology criteria) submitted to IAI (mono, pauci or polyarticular injection).
Assessment: a “blinded” observer prospectively evaluated joints at one week (T1), four weeks
(T4),  twelve weeks (T12) and 24 weeks (T24) after IAI. Outcome measurements included
Visual Analogue Scale (0-10 cm) at rest, in movement and for swollen joints. Clinical,
demographic and variables related to injection at baseline were analyzed according to IAI
response.
Results: We studied 289 patients with RA (635 joints) with a mean age of 48.7 years (±10.68),
48.5% of them Caucasians, VAS for global pain = 6.52 (±1.73). Under univariate analysis,
the  variables relating the best responses following IAI (improvement > 70%) were: “elbow
and metacarpophalangeal (MCP) IAI, and functional class II”. Under multivariate analysis,
“males” and “non-whites” were the predictors with the best response to IAI at T4, while
“elbow and MCP IAI”, “polyarticular injection”, “use of methotrexate” and “higher total dose
of  TH” obtained the best response at T24.
Conclusion: Several predictors of good response to IAI in patients with RA were identiﬁed.
The  best-response predictors for TH IAI of long term were “inject elbow and MCP IAI” and“perform polyarticular injection”.
© 2014 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail: jnatour@unifesp.br (J. Natour).
http://dx.doi.org/10.1016/j.rbre.2014.08.016
2255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
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Inﬁltrac¸ões  intra-articulares  de  triancinolona  hexacetonida  na  artrite
reumatóide:  preditores  de  melhora  a  curto  e  longo  prazo
Palavras-chave:
Inﬁltrac¸ão
Triancinolona hexacetonida
Artrite reumatoide
Prognósticos
r  e  s  u  m  o
Objetivos: Identiﬁcar fatores preditores de resposta à inﬁltrac¸ão intra-articular (IIA) com
hexacetonide de triancinolona (HT).
Métodos: Este estudo foi realizado em pacientes com artrite reumatoide (AR) (segundo
critérios do American College of Rheumatology) submetidos à IIA (inﬁltrac¸ão mono, pauci ou
poliarticular).
Avaliac¸ão: Um observador “cego” avaliou prospectivamente as articulac¸ões uma  semana
(T1), quatro semanas (T4), 12 semanas (T12) e 24 semanas (T24) após IIA. As medidas
de  desfecho foram Escala Visual Analógica (0-10 cm) em repouso, em movimento e para
articulac¸ões  edemaciadas. As variáveis clínicas e demográﬁcas e aquelas relacionadas à
inﬁltrac¸ão  no início do estudo foram analisadas de acordo com a resposta à IIA.
Resultados: Foram estudados 289 pacientes com AR (635 articulac¸ões) com média de idade
de  48,7 (± 10,68) anos; 48,5% eram caucasianos, EVA para dor global = 6,52 (± 1,73). Na análise
univariada, as variáveis relativas às melhores respostas seguida à IIA (melhora >70%) foram:
“IIA  no cotovelo e metacarpofalangeanas (MCF)” e “classe funcional II”. Na análise multi-
variada, “homens” e “não brancos” foram os preditores com melhor resposta à IIA em T4,
enquanto “IIA no cotovelo e MCF”, “inﬁltrac¸ão poliarticular”, “uso de metotrexato” e “dose
total maior de HT” obtiveram a melhor resposta em T24.
Conclusão: Foram identiﬁcados diversos fatores preditores de boa resposta à IIA em pacientes
com AR. Os preditores de melhor resposta para IIA de HT em longo prazo foram “realizar
IIA  no cotovelo e MCF” e “realizar inﬁltrac¸ão poliarticular”.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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lthough intra-articular injection of corticosteroids (IAIC) has
een a commonly used procedure among rheumatologists
or over half a century,1 few studies have been conducted to
emonstrate its beneﬁts in accordance to scientiﬁc method-
logy.
Rheumatoid arthritis (RA) is the rheumatic condition
hat most severely affects the joints. Pannus, the hyper-
rophic and hyperplasic synovial membrane formed, is an
ggressive tissue that damages articular and periarticular
tructures, whether through the release of metalopro-
einases or its mechanical invasion of the surrounding joint
pace.2–4
Even though RA treatment has evolved in recent decades
ith the advent of immunobiological therapy allied with
isease-modifying antirheumatic drugs (DMARDs),5 patients
ith mono or oligoarticular synovitis may persist. In these
ases, IAIC can be a useful therapeutic tool.
It is known that triamcinolone hexacetonide (TH) is
he drug of choice for intra-articular treatment of RA,
iven its synovial atrophying properties and slow absorption
rom the injection site.6–13 On the other hand, if injected
utside of the joint, it can cause serious adverse local
ffects.14
Though some concepts concerning IAIC have been estab-
ished, few studies have been conducted to evaluate response
redictors in adult RA patients.15 In addition, to the best of our
nowledge, none of them evaluated TH IAIC response predic-
ors in patients with established RA.The aim of this study was to identify variables (clini-
cal, demographic and related to injection) that serve as the
best predictors of response to TH IAIC over short term (4
weeks) and long term (24 weeks) in patients with established
RA.
Materials  and  methods
A prospective non-controlled study was conducted on a cohort
of patients with established RA receiving treatment at the
Interventional Rheumatology Unit at Universidade Federal de
São Paulo (UNIFESP), São Paulo, Brazil.
Patients were classiﬁed according to American College of
Rheumatology – ACR16 criteria, and had been referred for IAIC
(mono, pauci or polyarticular).
Inclusion criteria were: age between 18 and 65; functional
class II or III;17 stable DMARD for the last 3 months; stable
oral corticosteroid for the last month; indication for IAIC injec-
tion (persistent synovitis with swelling and articular pain) and
must have signed the informed consent form.
Exclusion criteria were: IAIC in any joint within the last 6
months; any symptoms of systemic or articular infection; any
form of clotting disturbance; diagnosis of diabetes mellitus or
systemic arterial hypertension; known allergy to contrasts or
radioisotopes, and suspicion of pregnancy.
Most of the joints injections were not guided. Fluoroscopy
and ultrasound were used for guided injections, as needed.
Image-guided IAIC was recommended in cases of difﬁcult
blind access or where the use of radioisotopes was recom-
mended.
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Written informed consent was obtained from all subjects, and
the Ethics Committee of the university approved the study.
Table 1 – Demographic, related to disease and related to
injection data of the baseline sample.
Variables
Age in years, mean (+SD) 47.6 (+10.81)
Disease duration in years, mean (+SD) 11.2 (+8.23)
Women:men ratio 9:1
Global pain, VAS mean (+SD) 6.52 (+1.73)
White skin color n (%) 308 (48.5)
Functional class II N (%)/III n (%) 368 (58.0)/267 (42.0)
Using methotrexate n (%) 469 (73.9)
Using leﬂunomide n (%) 103 (1.2)
Using chloroquine n (%) 164 (25.8)
Using immunobiological drugs n (%) 1 (0.2)
Using oral corticosteroid n (%) 467 (73.5)
Rheumatoid factor positivity n (%) 411 (64.7)
Extra-articular disease n (%) 71 (11.2)
Previous IAIC n (%) 300 (47.2)
Polyarticular injection n (%) 312 (49.1)
Image-guided IAIC n (%) 90 (14.2)
Radioisotopes in IAIC n (%) 30 (4.7)
Number of joints injected:
Shoulder n (%) 35 (5.5%)
Elbow n (%) 48 (7.6%)
Wrist n (%) 160 (25.2%)
MCP n (%) 142 (22.4%)
Knee n (%) 152  (23.9%)
Ankle n (%) 98 (15.4%)
Patientes and joints evaluated from T0 to:
T4 289/635 joints
T12 185/403 joints
T24 35/313 joints218  r e v b r a s r e u m a t
Intervention
Patients received IAIC in one or more  of the following joints:
shoulder (glenohumeral), elbow, wrist, metacarpophalangeal
(MCP), knee and ankle. The procedure was carried only at
the baseline by the same rheumatologist, with over ten years
of experience in interventional rheumatology (RNV Furtado).
The IAIC was mono, pauci (up to three inﬁltrations at once)
or polyarticular (4 to 8 simultaneous IAIC), depending on the
number of joints indicating pain and swelling.
The only corticosteroid used was triamcinolone hexace-
tonide (20 mg/mL). Depending on the size of the joint space,
dose of corticosteroid was considered low (1), medium (2) and
high (3). The dose of TH used for each joint studied were:
shoulder, 80 mg  (3); elbow, 40 mg  (2) or 60 mg  (3); wrist, 30 mg
(2) or 40 mg  (3); metacarpophalangeal, 10 mg  (2) or 20 mg  (3);
knee, 40 mg  (1), 60 mg  (2) or 80 mg  (3); and ankle, 40 mg  (2) or
60 mg  (3).
Patients received the IAIC procedure in dorsal decumbency
after the injection site had been cleansed with topical povi-
dine. Only sterile needles and syringes were used. Xylocaine
chloride 2% without vasoconstrictor was used for anesthetic
purpose. TH was only administered once the needle had been
corrected positioned inside the joint space.
In patients submitted to knee IAIC with radioisotopes, all
the safety norms for radioactive material handling were fol-
lowed. The dose applied was 5 mCi  Yttrium-90 plus 40 mg  of
TH, or 15 mCi  Samarium-153 hydroxyapatite plus 40 mg  of TH,
depending on availability. These drugs were used only in cases
of refractory synovitis only in the knee.
All patients were warned to rest for a period of 48 hours
after injection, only allowed to move around to meet their
physiological needs. An orthotic immobilizer was used in case
of IAI with radioisotopes.
Assessment
“Blinded” examination at T0 (baseline), T1, T4, T12, and T24
weeks post-injection were performed. Outcome measures
included: visual analogue scale (0-10 cm)  for joint pain at rest
(VASr); visual analogue scale (0-10 cm)  for joint pain in move-
ment (VASmv) and visual analogue scale for swollen joints
(VASs).
IAIC response was assessed in relation to the injected joint
(rather than the patient as a whole) and was measured as per-
centage (%) of improvement on the VASr, VASmv and VASs
scales for each joint at times T1, T4, T12 and T24. Improvement
between 50% and 70% was considered moderate, and over 70%
was considered signiﬁcant. The association between improve-
ment percentages for VASr, VASmv and VASs was made in
isolation (50%-70% and > 70%) and concomitantly (improve-
ment > 50% in all three VAS at once) and multiple baseline
variables were factored in.
Baseline variables considered under this analysis were:
demographic (gender, age and skin color – white or non-
white); related to disease (duration, functional class II or III,
presence of rheumatoid factor, DMARDS in use, use of oral
corticosteroid and presence of extra-articular disease) and
related to injection (joint injected, previous IAI, number of 0 1 5;5 5(3):216–222
joints injected, TH dose, total TH dose per patient, image
guided IAI and use of radioisotope or contrast agent).
Statistical  analysis
The continuous variables were described in mean and
standard deviation (SD), and the categorical variables in fre-
quencies and percentages.
Comparison between continuous and categorical baseline
variables was made using Kruskal-Wallis univariate analysis,
while comparison between categorical baseline variables was
performed using chi-square or Fisher’s exact tests.
Only those joints showing improvement percentages
higher than 50% concomitantly for all three VAS (VASr, VASmv
and VASs) were subjected to multivariate logistic regression
analysis, with the chance of improvement measured in Odds
Ratio (OR) (IC 95%).
Signiﬁcant p value was set at 5%.
Ethicsn (%), frequency (percentage); SD, standard deviation; IAIC, intra-
articular injection with corticosteroid; MCP, metacarpophalangeal
joints; VAS, Visual Analogue Scale.
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53SmPHYP was provided by Instituto de Pesquisas Energéti-
as e Nucleares do Brasil (IPEN). 90Y was imported by IPEN
rom Cis Bio Schering International (France). All procedures
hat used radioisotopes were performed under biosafety rules
t the Nuclear Medicine Sector.
esults
e  studied 289 patients with RA with a mean age of 47.6
ears (SD ± 10.81) and mean disease duration of 11.2 years
SD ± 8.23), 48.5% white and women-to-men ratio of 9:1, VAS
or global pain 6.52 (±1.73). Monoarticular injection occurred
n 175 patients (60.55%); pauciarticular injection in 68 patients
23.53%), and polyarticular injection in 46 patients (15.92%). Six
undred and thirty-ﬁve (635) joints were injected and prospec-
ively studied through T4; 403 through T12, and 313 through
24. Table 1 presents the demographic data and data related
o disease and related to injection for the sample patients.Baseline variables that did not correlate statistically with
AS improvement at any of the assessment times were:
mage-guided IAIC, use of radioisotopes and use of contrast
n IAIC.
Table 2 – Association between improvement of 50%-70% and > 7
and the presence of baseline predictors.
VASmv
Improvement (%)
VA
Imp
T4 T24 T4 
Baseline predictors 50-70 >70 50-70 >70 50-70 
IAIC in elbow - + - - - 
IAIC in wrist - - - - - 
IAIC in MCP -  - - + - 
IAIC in knee - + + - - 
Size of TH dose per
IAIC (1/2/3)
-  - - + (3) - 
Polyarticular injection - - - + - 
Total TH dose per
patient (H/L)
-  - - + (H) - 
Age (H/L) - - - + (L) - 
Gender (fem/male) - - - - - 
Skin color (W/NW) - - - + (NW) - 
Functional class (2/ 3) - - - + (2) - 
Extra-articular disease
(Y/N)
- - - + (Y) - 
Disease duration (H/L) - + (H) - - - 
Use of chloroquine
(Y/N)
-  - - - - 
MTX (H/L dosage) - - - - + (H) 
Use of LFU (Y/N) - - - + (Y) - 
Total number of
DMARDS (H/L)
-  - - - - 
Previous IAIC (Y/N) - - - - - 
Use of NSAIDS (Y/N) + (N) - - - - 
Dose of OC (H/L) - - - - - 
IAIC, Intra-articular injection with corticosteroid; VASmv, Visual Analogue
rest; VASs, Visual Analogue Scale for swollen joints; TH, triamcinolone he
2-medium, 3-high; RF: rheumatoid factor; MTX, methotrexate; LFU, leﬂuno
lower; Y, yes; N, no; W, White; NW, Non-white; Fem, female; OC, oral cortic 5;5 5(3):216–222 219
Univariate analysis (Kruskal-Wallis) between VAS improve-
ments and baseline variables revealed various IAIC response
predictors.
In terms of moderate improvement (50-70%) on post-IAIC,
the statistically associated baseline variables were (p < 0.05):
VASmv, at T4 – lower use of NSAIDs at baseline; at T24 – knee
IAIC; VASr, at T4 – higher dose of MTX; at T12 – knee IAIC,
higher total TH dose per patient; at T24 – wrist IAIC, longer dis-
ease duration, higher use of NSAIDs at baseline; VASs,  at T12-
knee IAIC, medium dose of TH per IAIC, male gender (Table 2).
The best outcome predictors for signiﬁcant improvement
post-IAIC (> 70%) were (p < 0.05): VASmv, at T4 – elbow and
knee IAIC, longer disease duration; at T12 – MCP  IAIC, higher
dose of TH per IAIC, polyarticular injection, higher total dose
of TH per patient, lower mean age, functional class II, use of
chloroquine, no use of leﬂunomide; no previous IAIC; at T24 –
MCP  IAIC, higher TH dose per IAIC, higher total TH dose per
patient, polyarticular injection, lower mean age, non-white
skin color, functional class II, more  extra-articular disease, no
use of leﬂunomide; VASr, at T4 – wrist and knee IAIC, higher TH
dose per IAIC, use of methotrexate; at T12 – MCP  IAIC, higher
TH dose per IAIC, higher TH dose per patient, non-white skin
color, functional class II, no use of leﬂunomide; at T24 – MCP
0% on VASmv, VASr and VASs assessments after IAIC
Sr
rovement (%)
VASs
Improvement (%)
T24 T4 T24
>70 50-70 >70 50-70 >70 50-70 >70
- - - - + - +
+ + - - - - -
- - + - + - +
+ - - - - - +
+ (3) - + (3) - + (3) - + (3)
- - + - + - +
- - + (H) - + (H) - + (H)
- - - - - - -
- - - - - - -
- - + (NW) - - - -
- - + (2) - - - + (2)
- - - - - - -
- + (L) - - - - -
- - - - - - -
+ (H) - - - - - -
- - + (S) - + (N) - + (N)
- - - - + (H) - -
- - - - - - -
- - - - + (Y) - -
- + (H) + (L) - - - -
 Scale for Pain in movement; VASr, Visual Analogue Scale for pain at
xacetonide; MCP, metacarpophalangeal joint; Size of TH dose 1- low,
mide; DMARD, disease-modifying anti-rheumatic drug; H, higher; L,
osteroid; Statistical test, Kruskal Wallis. +, p < 0.05; -, p > 0.05.
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Table 3 – Association between > 50% concomitant
improvement on VASmv, VASr and VASs post-IAIC and
the presence of variables at baseline.
Variables T4 T24
OR P OR p
Joint type (compared to the
knee)
1. Elbow NS NS 4.4 0.008
2. Wrist 0.59 0.03 NS NS
3. MCP 0.46 0.002 2.75 < 0.001
4. Shoulder NS NS NS NS
5. Ankle 0.55 0.03 NS NS
Poly-injection (yes/no) 0.26 < 0.001 2.37 0.02
Sex (male/female) 2.19 0.008 NS NS
Skin color (non-white/white) 2.47 < 0.001 0.55 0.04
Rheumatoid factor (yes/no) NS NS 0.34 < 0.001
Functional class (3/2) NS NS 0.42 0.003
Chloroquine (yes/no) 0.61 0.03 0.52 0.03
MTX (yes/no) NS NS 1.90 0.013
Use of oral corticosteroid NS NS 0.95 0.02
Total Dose of TH 0.99 < 0.001 1.00 0.02
IAIC, Intra-articular injection with corticosteroid; VASmv, Visual
Analogue Scale for pain in movement; VASr, Visual Analogue Scale
for pain at rest; VASs, Visual Analogue Scale for swollen joints;
OR, odds ratio; TH, triamcinolone hexacetonide; MTX, methotrex-
ate; MCP, metacarpophalangeal joint; NS, no statistical signiﬁcancy
term. Higher dose of TH correctly introduced into the joint
space might prove to be more  effective than a lower dose,(p > 0.05); Statistical test, multivariate logistic regression.
IAIC, higher TH dose per IAIC, polyarticular injection, higher
total dose of TH per patient, non-white skin color, functional
class 2, no use of leﬂunomide, less use of oral corticosteroid;
VASs, at T4 – elbow and MCP  IAIC, higher TH dose per IAIC,
polyarticular injection, higher total TH dose per patient, no
use of leﬂunomide, lower number of DMARDS, NSAID use; at
T12 – MCP  IAIC, polyarticular injection, higher total TH dose
per patient, no previous injection, lower dose of oral cortico-
steroids; at T24 – elbow, MCP  and knee IAIC, higher TH dose
per IAIC, polyarticular injection, higher total dose of TH per
patient, functional class II, no use of leﬂunomide (Table 2).
Multivariate logistic regression also showed that some
of the variables presented at baseline were considered IAIC
response predictors (Table 3).
In the short term (T4), the only variables that were predic-
tors of best IAIC response were: “male gender” and “non-white
skin color”. On the other hand, “wrist, MCP  and ankle
IAIC”, “do polyarticular injection”, “be using chloroquine” and
“higher total dose of TH per patient” were the predictors for
the worst IAIC response in the short term.
In the long term (T24), various baseline variables were
predictors of the best IAIC response, the most important of
which was “do elbow IAIC” (with a 4.4 times higher chance
of success), followed by “do MCP  IAIC”, “do polyarticular
injection”, “be using MTX” and “higher total dose of TH”
per patient (Table 3). The baseline variables associated with
the worst long-term IAIC response were: “non-white skin
color”, “rheumatoid factor positivity”, “functional class III”,
and “be using chloroquine and oral corticosteroid”. Multivari-
ate logistic regression did not show any medium-term (T12)
improvement predictor. 0 1 5;5 5(3):216–222
Only mild and transitory local adverse effects were
observed. Post-IAIC inﬂammatory ﬂare was observed in
37.82% of the patients (related by the patients but not observed
by the blinded observer at T1). Skin atrophy, skin hypochromic
and articular instability were observed in 1.9%, 15.3% and 2.0%
of the patients, respectively.
Discussion
This was a prospective, non-controlled study conducted on a
cohort of patients with established RA receiving TH IAIC injec-
tion, a description of a great experience of our group. Though
known as the most effective corticosteroid for intra-articular
use,6–8,10–12 we are unaware of other similar studies in which
TH was used as an IAIC drug.
Our group has already published few studies in which
RA patients were submitted to TH IAIC injection. Monoar-
ticular and polyarticular IAIC effectiveness was considered
superior to systemic use of corticosteroids;10,11 ankle was con-
sidered the joint with lowest accuracy for blinded IAIC;6 the
use of ultrasound to guide TH injection did not increase its
effectiveness in wrists joint,12 and the use of radioisotopes
(Yttrium-90 and Samarium-153-particulate hydroxyapatite)
did not improved TH IAIC effectiveness when compared to
injection of TH IAIC alone.7,8
Uncommon TH doses, as 20 mg  for MCP  joint or 80 mg for
knee joint, were used in our study. The ideal TH doses for IAIC
have not been already established, but the most commonly
used dosages are 40 mg of TH for large joints and 10-20 mg  for
small to medium-sized joints.6,11,14,18,19 Some authors, how-
ever, have used optimized doses of TH somewhat similar to
ours,6,11,14 without the occurrence of any signiﬁcant adverse
effects.
In our study, the use of radioisotopes was not related to any
articular improvement at any of the evaluation time’s post-
IAIC. Increased IAIC effectiveness when associated with the
use of the Yttrium-90 and Samarium-153 Hydroxyapatite has
been questioned by previous studies.7,8,20,21
Univariate analysis found that baseline variables as “higher
TH doses applied via IAIC and per patient”, “polyarticular
injection” and “be using leﬂunomide” were associated with
the worst IAIC responses. Perhaps a more  aggressive TH dose
administered via IAIC and a greater number of joints injected
are associated with higher post-IAIC articular ﬂare and, there-
fore, with a clearer perception of short-term aggravation.
On the other hand, the variables “do MCP” and “do elbow”
IAIC, “functional class II” and “higher doses of TH per joint
and per patient” were repeatedly associated with best IAIC
responses, especially over the long term. Some of these vari-
ables have already been shown to be best response predictors
for IAIC using TH, most notably “do elbows” and “do MCP”
IAIC.6,11 However, “functional class III”, “higher oral dose of
corticosteroid” and “higher dose of TH per patient” had not
been identiﬁed as good IAIC response predictors over the longthough this conclusion needs to be conﬁrmed with prospec-
tive studies.
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Other studies that evaluate IAIC response predictors15,22–25
ave been already published, but few of them used TH as the
hosen corticosteroid.22,24
In the study conducted by Green et al.,15 ﬁfty-one patients,
ith less than or equal to ﬁve joints with synovitis, were
reated with methylprednisolone IAIC. Predictors of response
ere studied being the primary endpoint a complete response
t 12 weeks. Twenty-nine patients (57%) had a complete
esponse at 2 weeks. The best predictor of response at 12 and
6 weeks was the complete response at 2 weeks.15 The present
tudy used TH rather than methylprednisolone; it evaluated a
igher number of patients and did not study the relationship
etween IAIC responses obtained at the ﬁrst assessment time
nd those obtained during subsequent evaluation times.
Eder et al.25 evaluated IAIC responses in two hundred and
wenty patients with psoriatic arthritis submitted to 245 IAIC.
linical factors associated with good response included dura-
ion of psoriasis [Odds Ratio (OR) 1.03] and the use of MTX
r anti-TNF agents at the time of injection (OR 2.68). Injec-
ion into large joints (OR 4.58), elevated sedimentation rate (OR
5.0) and MIF  polymorphism (OR 3.2) were factors associated
ith relapse, whereas absence of clinical and/or radiographic
amage (OR 0.23) and duration of disease (OR 0.92) reduced
isk of relapse.25 Similarly to our study, Eder et al.25 also stud-
ed a greater number of patients and found that the use of MTX
as a predictive factor of IAIC response. However, the diseases
tudied were different, which make it difﬁcult to compare both
ets of results.
Hetland et al.23 evaluated betamethasone IAIC response
n 160 patients with early RA. One thousand three hun-
red and seventy-three joints (ankles, elbows, knees, MCP,
etatarsophalangeal, proximal interphalangeal (PIP), shoul-
ers, wrists) were injected (once or repeated injections) during
 years. All joint areas had good 2-year joint injection sur-
ival, longest for PIP joints: 73.7%. A higher MRI  synovitis score
f MCP  joints and anti-CCP-negativity were associated with
oorer joint injection survival, whereas IgM-RF and C-reactive
rotein were not. Like our study, IAIC injection of small hand
oint was a good IAIC-response predictor. However, the pres-
nce of positive rheumatoid factor was associated with worse
AIC responses at T24 and repeated injections in the same
oint space were not performed. The time of onset of RA and
he drug injected were important differences between the
tudies.
According to our multivariate logistic regression analy-
is, an association with best IAIC response was observed in
nly seven baseline variables. “Being male” and “non-white
kin color” was associated with best IAIC responses over the
hort term. However, the stronger associations with best IAIC
esponse over the long term (24 weeks) were observed for the
ariables “do elbow and MCP  IAIC”, “do polyarticular injec-
ion”, “be using methotrexate” and “higher total dose of TH per
atient”. As initially shown by univariate analysis, “do elbow”
nd “do MCP” IAIC remained the baseline variables predictive
f best IAIC response. The beneﬁt of polyarticular injection,
hich implies the use of a higher total dose of corticos-
eroid per patient, was proven by previous controlled studies
sing methylprednisolone and TH.11,26 As already suggested
y Eder et al.,25 “be taking methotrexate”, given its disease-
odifying action on synovitis, favor a positive IAIC response in 5;5 5(3):216–222 221
comparison to when this drug is not in use in psoriatic arthritis
patients.
In the present study “do MCP IAIC”, “do polyarticular injec-
tion” and “higher total dose of TH per patient” were both worst
and best-response predictors over the short and long term,
respectively. This suggests that post-IAIC articular ﬂare may
be cause of the worst responses in the short term.
The worst long-term response predictors – “having a posi-
tive rheumatoid factor and functional class III” and “be using
oral corticosteroid at the time of IAIC” – suggest a worse IAIC
response in patients suffering from a more  serious condi-
tion. However, “be using chloroquine” is associated with worse
IAIC response over both the short and long term. Perhaps
the mechanism of action of chloroquine interferes with intra-
articular-administered TH, a microcrystalline corticosteroid.
But this association has never been studied, and a speciﬁc
prospective study is needed to clarify this doubt.
One of the limitations of this study is that anticitruline anti-
bodies were not measured in our sample patients. As only 0.2%
of the patients studied were receiving immunobiological ther-
apy, predictive variables for best IAIC response identiﬁed in
this study cannot be extrapolated for those patients receiving
this therapy.
Finally, this is the ﬁrst study to identify, in RA patients,
baseline predictors for worst and best responses to IAIC with
TH, the most atrophying corticosteroid for intra-articular use.
Deﬁning predictive factors for IAIC response may prove to be
extremely helpful in obtaining more  adequate recommenda-
tions for IAIC, and, therefore, better therapeutic management
for RA patients.
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